Clinical Oncology
Volume 22, Issue 2 , Pages 136-139 , March 2010

Should We Routinely Offer a Second Admission for Radioiodine to Patients with High-risk Differentiated Thyroid Cancer?

  • G.E. Gerrard

      Affiliations

    • Corresponding Author InformationAuthor for correspondence: G.E. Gerrard, St James Institute of Oncology, St James's Hospital, Becket Street, Leeds LS9 7TF, UK. Tel: +44-113-2068336; Fax: +44-113-2067534.
    • ,
  • L. O'Toole
    • ,
  • F. Roberts

Received 1 October 2009 ,Revised 14 December 2009 ,Accepted 21 December 2009.

References 

  1. Spitzweg C, Harrington KJ, Pinke LA, Vile RG, Morris JC. Clinical review 132: the sodium iodide symporter and its potential role in cancer therapy. J Clin Endocrinol Metab. 2001;86(7):3327–3335
  2. British Thyroid Association . Guidelines for the management of thyroid cancer. British Thyroid Association, Royal College of Physicians. Report of the Thyroid Cancer Guidelines Update Group 2nd edn. London: Royal College of Physicians; 2007;
  3. Luster M, Clarke SE, Dietlein M, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008;35:1941–1945
  4. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JWA, Wiersinga W. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154:787–803
  5. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167–1214

PII: S0936-6555(10)00005-1

doi: 10.1016/j.clon.2010.01.002

Clinical Oncology
Volume 22, Issue 2 , Pages 136-139 , March 2010

Article Tools